Last reviewed · How we verify

NCT03716037

Improving Physical and Psychosocial Well-being of African American Older Adults

Completed NA Last updated 29 May 2024
What this trial tests

NA trial testing Physical Activity for Life (PAL) in Physical Activity in 41 participants. Completed in 31 December 2022.

Timeline
22 September 2021
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorUniversity of Alabama, Tuscaloosa
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment41
Start date22 September 2021
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Alabama, Tuscaloosa

Who can join

Adults 65 to 100, any sex, with Physical Activity or Psychosocial Stressors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed research effort will: The purpose of this study is as follows: 1. Test the feasibility and acceptability of an eight-week community-based exercise program among AA older adults living in rural areas. 2. Determine whether participation in physical exercise through a community-based exercise program in comparison with an attentional control group: a) improves physical well-being b) improves psychosocial well-being

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Physical Activity

Currently open trials in the same condition.

Other University of Alabama, Tuscaloosa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03716037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing